Patients with mantle cell lymphoma may soon gain access to ibrutinib (Imbruvica) on the PBS. At its March 2018 meeting the Pharmaceutical Benefits Advisory Committee (PBAC) recommended expansion of the PBS listing for the immune therapy to include patients with relapsed/refractory mantle cell lymphoma (MCL). The PBAC said its recommendation for MCL “reflected the high ...
PBS listings approved for haematological cancer drugs and biosimilars
By Michael Woodhead
25 Apr 2018